Advertisement

Annals of Hematology

, Volume 98, Issue 8, pp 1995–1997 | Cite as

Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman’s disease

  • Kazutoshi Ebisawa
  • Yosuke Masamoto
  • Junji Tokushige
  • Hiroshi Nishi
  • Kenjiro Honda
  • Munetoshi Hinata
  • Kazuhiro Toyama
  • Masaomi Nangaku
  • Mineo KurokawaEmail author
Letter to the Editor
  • 161 Downloads

Notes

Compliance with ethical standards

Full informed consent was obtained from the patient in this report for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

Kazuhiro Toyama has the following financial relationship to disclose. Honoraria (lecture fee) from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Masaomi Nangaku has the following financial relationships to disclose. Honoraria (lecture fee) and research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). Mineo Kurokawa has the following financial relationship to disclose. Research funding from Chugai Pharmaceutical Co., Ltd. (tocilizumab). The other authors (Drs K.E., Y.M., J.T., H.N., K.H., M.H.) declared that they had no relevant financial relationships to disclose.

References

  1. 1.
    Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fossa A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 129(12):1646–1657.  https://doi.org/10.1182/blood-2016-10-746933 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Yuan XG, Hu W, Chen FF, Huang BF, Zhao XY (2011) Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases. Clin Exp Nephrol 15(6):921–926.  https://doi.org/10.1007/s10157-011-0499-9 CrossRefPubMedGoogle Scholar
  3. 3.
    Kawabata H, Kadowaki N, Nishikori M, Kitawaki T, Kondo T, Ishikawa T, Yoshifuji H, Yamakawa N, Imura Y, Mimori T, Matsumura Y, Miyachi Y, Matsubara T, Yanagita M, Haga H, Takaori-Kondo A (2013) Clinical features and treatment of multicentric castleman’s disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 53(1):69–77CrossRefPubMedGoogle Scholar
  4. 4.
    Estrada CC, Paladugu P, Guo Y, Pace J, Revelo MP, Salant DJ, Shankland SJ, D’Agati VD, Mehrotra A, Cardona S, Bialkowska AB, Yang VW, He JC, Mallipattu SK (2018) Kruppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. JCI Insight 3(12).  https://doi.org/10.1172/jci.insight.98214
  5. 5.
    Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, McCarthy ET, Srivastava T, Domen J, Tormo A, Gauchat JF (2015) Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family. J Immunol Res 2015:714964.  https://doi.org/10.1155/2015/714964 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kazutoshi Ebisawa
    • 1
  • Yosuke Masamoto
    • 1
  • Junji Tokushige
    • 1
  • Hiroshi Nishi
    • 2
  • Kenjiro Honda
    • 2
  • Munetoshi Hinata
    • 3
  • Kazuhiro Toyama
    • 1
  • Masaomi Nangaku
    • 2
  • Mineo Kurokawa
    • 1
    • 4
    Email author
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineThe University of TokyoTokyoJapan
  2. 2.Department of Nephrology and Endocrinology, Graduate School of MedicineThe University of TokyoTokyoJapan
  3. 3.Department of Pathology, Graduate School of MedicineThe University of TokyoTokyoJapan
  4. 4.Department of Cell Therapy and Transplantation MedicineThe University of Tokyo HospitalTokyoJapan

Personalised recommendations